

Meningococcal Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 114 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The meningococcal vaccines market is expected to register a CAGR of around 9.5% over the forecast period.

Key Highlights

- The COVID-19 pandemic had a significant impact on the market studied in the initial phase of the pandemic as people were not able to get the scheduled vaccinations owing to the lockdown and restrictions on hospital visits for non-emergency services. Various studies have found that few cases of meningitis suffered from COVID-19 over the years. For instance, as per the data from the BMC Infectious Disease report published in February 2022, one of the most common causes of invasive bacterial infections, such as pneumonia, sepsis, and meningitis, is streptococcus pneumonia. However, increased awareness program associated with education relating to the importance of treating infections is likely to boost the market growth.
- For instance, as per the November 2022 update from the Government of Western Australia Department of Health, the School-Based Immunization Program (SBIP) is likely to be supplying Diphtheria-tetanus-pertussis (dTpa), HPV (human papillomavirus), Meningococcal ACWY, and COVID-19 vaccines to the students from 2023 onwards. Hence, such immunization programs create a demand for preventive vaccines, which is anticipated to drive market growth over the forecast period.
- The major factors for the growth of the meningococcal vaccine market include the increase in public-private partnerships to support the development of vaccines at low cost and rising immunization programs and government initiatives.
- The increasing focus of companies to develop novel vaccines in the field of meningococcal disease is contributing to market growth. For instance, in April 2022, experts from the University of Maryland School of Medicine (UMSOM) announced a new study in which they are evaluating the pentavalent or five-in-one meningococcal conjugate vaccine (NmCV-5) among infants and young children in the meningitis belt of sub-Saharan Africa.
- This is the final investigation to undergo for obtaining the prequalification from the World Health Organization for this vaccine, and if it qualifies the same, it will be launched in the low-and-middle-income countries. Hence, with such new vaccines, the market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

studied is getting benefits. Also, there is a rising public-private partnership to support the development of vaccines and create awareness among the population. Hence, the Meningococcal vaccine market is expected to witness high growth over the forecast period. However, the high cost associated with the storage and supply of vaccines is expected to hinder market growth.

Meningococcal Vaccines Market Trends

Polysaccharide Vaccine is Expected to Witness High Growth Over the Forecast Period

- Internationally marketed meningococcal polysaccharide vaccines are bivalent (A and C), trivalent (A, C, and W-135), or tetravalent (A, C, Y, and W-135). The vaccines are purified, heat-stable, lyophilized capsular polysaccharides from meningococci of the respective serogroups. The vaccines have helped curb the exponential growth of the disease and are expected to do so in the future as well. This is expected to help the market growth.
- The polysaccharide vaccines continue to witness high traction from developing countries due to limited supply by few vaccine manufacturers; market forerunners are collaborating with local distributors to expand their footprint. Initiatives such as product approvals are another factor in segmental growth. For instance, in September 2022, Pfizer Inc.'s investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the US FDA for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Hexavalent anti-capsular polysaccharide (CPS) / cross-reactive material 197 glycoconjugates (GBS6) is an investigational maternal vaccine being developed to help prevent invasive Group B Streptococcus (GBS) in newborns. Thus, such approvals are expected to increase its adoption, which is expected to increase segmental growth over the forecast period.
- Data published in 2021 by the National Institute of Health (NIH) suggests that people with diabetes are two times more likely to be infected with meningitis. Diabetes is one of the most significant risk factors associated with meningitis. As per the 2022 data from the International Diabetes Federation, around 537 million people were living with diabetes across the globe in 2021. Diabetes is one of the leading risk factors associated with the infection of meningitis.
- Hence, owing to the above-mentioned factors, it is expected that the segment will witness healthy growth over the forecast period.

North America is Expected to Hold Largest Market Share over the Forecast Period

- The United States is expected to be the largest meningococcal vaccine market owing to the rising awareness of the disease and the presence of better healthcare infrastructure. The rates of meningococcal disease have been declining in the United States since the 1990s. As per the data published by the Centers for Disease Control and Prevention (CDC), there has been an outbreak of meningococcal diseases in Florida, United States, in 2021. In an effort to contain this outbreak, the CDC has strongly recommended that gay and bisexual men residing in Florida receive the MenACWY vaccine. This proactive measure has raised awareness among the population and significantly increased the demand for meningococcal vaccines across the nation.
- As the United States has the most developed healthcare system across the globe, vaccination is the major priority for the government in the country. As a result, timely vaccination is carried out in the United States, which is further augmenting the growth of the meningococcal vaccine market in the country.
- For instance, in the United States, the Meningitis Foundation of America (MFA) is a non-profit organization dedicated to providing information and support to individuals who have had personal experiences with meningitis. Also, this foundation is to create awareness in the public and the medical communities about the initial symptoms of meningitis. Thus, owing to the above-mentioned factors, the meningococcal vaccine market is expected to witness steady growth over the forecast period.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- In addition, the COVID-19 pandemic reduced the vaccination rate in the United States during the years 2020 and 2021. For instance, as per the data published by WHO in May 2022, only 25 other vaccines apart from COVID-19 were introduced during the year 2021 in the United States. Additionally, the coverage of vaccination rate dropped from 86% in 2019 to 81% in 2021. However, currently, vaccinations are being given as per the schedule, and it is believed that the vaccination rate will go high rapidly in the coming years.

- Hence, owing to the above-mentioned factors, it is believed that the United States will witness a strong share in the global meningococcal vaccine market.

Meningococcal Vaccines Industry Overview

The market studied is a moderately fragmented market owing to the presence of a few major market players. The key market players are employing various strategies such as partnerships, new product launches, and expansion to sustain themselves in the market. Some of the market players are Bio-Manguinhos, Biomed Pvt. Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi Pasteur Inc., and Serum Institute of India Ltd., among others.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
 - 4.2.1 Increase in Public-Private Partnerships to Support Development of Vaccines at Low Cost
 - 4.2.2 Rising Immunization Programs and Government Initiatives
- 4.3 Market Restraints
 - 4.3.1 High Cost Associated with Storage and Supply of Vaccines
- 4.4 Porter's Five Forces Analysis
 - 4.4.1 Threat of New Entrants
 - 4.4.2 Bargaining Power of Buyers/Consumers
 - 4.4.3 Bargaining Power of Suppliers
 - 4.4.4 Threat of Substitute Products
 - 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

- 5.1 By Type
 - 5.1.1 Polysaccharide Vaccines

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.2 Conjugate Vaccines
- 5.1.3 Combination Vaccines
- 5.1.4 Other Types
- 5.2 By End-User
 - 5.2.1 Hospitals
 - 5.2.2 Pharmacy Stores
 - 5.2.3 Other End-Users
- 5.3 Geography
 - 5.3.1 North America
 - 5.3.1.1 United States
 - 5.3.1.2 Canada
 - 5.3.1.3 Mexico
 - 5.3.2 Europe
 - 5.3.2.1 Germany
 - 5.3.2.2 United Kingdom
 - 5.3.2.3 France
 - 5.3.2.4 Italy
 - 5.3.2.5 Spain
 - 5.3.2.6 Rest of Europe
 - 5.3.3 Asia-Pacific
 - 5.3.3.1 China
 - 5.3.3.2 Japan
 - 5.3.3.3 India
 - 5.3.3.4 Australia
 - 5.3.3.5 South Korea
 - 5.3.3.6 Rest of Asia-Pacific
 - 5.3.4 Middle East and Africa
 - 5.3.4.1 GCC
 - 5.3.4.2 South Africa
 - 5.3.4.3 Rest of Middle East and Africa
 - 5.3.5 South America
 - 5.3.5.1 Brazil
 - 5.3.5.2 Argentina
 - 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

- 6.1 Company Profiles
 - 6.1.1 Bio-Manguinhos
 - 6.1.2 Biomed Pvt. Ltd
 - 6.1.3 GlaxoSmithKline plc
 - 6.1.4 Merck & Co., Inc.
 - 6.1.5 Novartis AG
 - 6.1.6 Pfizer Inc.
 - 6.1.7 Sanofi Pasteur Inc.
 - 6.1.8 Serum Institute of India Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Meningococcal Vaccines - Market Share Analysis, Industry Trends & Statistics,
Growth Forecasts 2019 - 2029**

Market Report | 2024-02-17 | 114 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-25"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

